Related Experiment Video
Updated: Jul 20, 2026

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis
Published on: October 26, 2020
The role of alpha 1-blockers in combination therapy for hypertension
1Division of Hypertension and Vascular Medicine, Massachusetts General Hospital, Boston 02114, USA.
Insights
For many patients, hypertension (high blood pressure) requires more than one medication. Adding an alpha1-blocker effectively improves blood pressure control and offers additional health benefits.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Antihypertensive monotherapy achieves adequate blood pressure control in less than 50% of patients, particularly those with stage 2-3 hypertension.
- Hypertension frequently coexists with other conditions like type 2 diabetes mellitus and benign prostatic hyperplasia.
Purpose of the Study:
- To review clinical studies on the efficacy and tolerability of alpha1-blocker add-on therapy for inadequately controlled hypertension.
- To explore the additional therapeutic benefits of alpha1-blockers beyond blood pressure management.
Main Methods:
- Review of clinical studies evaluating alpha1-blockers (doxazosin, terazosin, prazosin) as add-on therapy.
- Analysis of effects on blood pressure control, tolerability, serum lipid profile, and coexisting conditions.
Main Results:
- Add-on therapy with alpha1-blockers is effective and well-tolerated for improving blood pressure control in patients with resistant hypertension.
- Alpha1-blockers demonstrate a small positive effect on serum lipid profiles.
- Favorable or benign effects were observed in patients with coexisting type 2 diabetes mellitus and benign prostatic hyperplasia.
Conclusions:
- Alpha1-blocker add-on therapy is a valuable strategy for achieving blood pressure control in patients with inadequately managed hypertension.
- Alpha1-blockers offer multifaceted therapeutic advantages, including lipid profile improvement and beneficial effects on common comorbidities.
Abstract:
Antihypertensive monotherapy provides adequate blood pressure control in less than 50% of patients with hypertension (BP > 140/90 mmHg), especially those with stage 2-3 disease. This article reviews clinical studies that demonstrate that add-on therapy with an alpha1-blocker (doxazosin, terazosin or prazosin) is an effective and well-tolerated regimen for improving blood pressure control in patients with inadequately controlled hypertension. Furthermore, alpha1-blockers have therapeutic benefits that go beyond blood pressure management. They have a small but positive effect on the serum lipid profile and they have favourable or benign effects on conditions that frequently coexist with hypertension, such as type 2 diabetes mellitus and benign prostatic hyperplasia.
Related Concept Videos
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...
Antihypertensive Drugs: Action of β1 Blockers
Antihypertensive Drugs: Angiotensin II Receptor Blockers
Antihypertensive Drugs: Direct Renin Inhibitors
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Hypertension IV: Drug Therapy and Lifestyle Modifications

